Table 2.

Univariable models for acceptance and adherence among 368 women offered tamoxifen

OR for accepted (n = 298) vs. declined (n = 71)OR for adherent (n = 214) vs. nonadherent (n = 59)
VariableOR (95% CI)POR (95% CI)P
Age1.02 (0.99–1.05)0.101.02 (0.99–1.05)0.16
European ancestry1.48 (0.86–2.54)0.150.54 (0.27–1.09)0.09
Family history0.98 (0.57–1.68)0.931.07 (0.59–1.96)0.82
SES
 1st vs. 2nd tertile0.97 (0.52–1.82)0.920.84 (0.40–1.80)0.66
 3rd vs 2nd tertile1.36 (0.73–2.53)0.340.66 (0.34–1.30)0.23
Having insurance1.29 (0.66–2.56)0.465.74 (2.51–13.11)<0.01
DCIS size1.00 (0.98–1.01)0.701.02 (1.00–1.04)0.05
DCIS grade
 2 vs. 11.11 (0.57–2.18)0.761.48 (0.72–3.04)0.29
 3 vs. 11.27 (0.59–2.74)0.542.06 (0.87–4.88)0.10
Surgical therapy (mastectomy vs. BCS)0.60 (0.31–1.15)0.120.68 (0.32–1.47)0.33
Radiotherapya2.82 (1.56–5.13)<0.012.23 (1.16–4.28)0.02
Complete local therapy2.26 (1.30–3.93)<0.012.62 (1.32–5.19)<0.01
Medical oncology consultation1.78 (1.01–3.15)0.051.62 (0.82–3.20)0.16

Abbreviation: BCS, breast conservation surgery.

  • aExcludes mastectomy patients since XRT is not indicated following mastectomy.